Zoonotic Disease Treatment Market is gaining traction as healthcare systems, pharmaceutical companies, and public health organizations place greater emphasis on preventing and managing infections transmitted between animals and humans. The market size is valued at USD 44.95 Billion in 2025 and is projected to reach USD 77.50 Billion by 2035, growing at a CAGR of 5.67% during the forecast period 2026–2035. Rising cases of rabies, tuberculosis, malaria, leishmaniasis, Ebola virus disease, and other zoonotic infections are contributing to demand for effective therapies and preventive solutions.
The increasing interaction between humans and animals, urbanization, changing environmental conditions, and greater awareness of infectious disease risks are encouraging investment in treatment and prevention. Healthcare providers are also adopting advanced antibiotics, antivirals, antifungals, immunoglobulins, vaccines, and other targeted therapies. Improvements in diagnostic technologies and drug delivery methods are helping clinicians identify infections more efficiently and initiate appropriate treatment sooner.
Download the Sample Report: https://www.snsinsider.com/sample-request/10134
Hospitals remain the leading end users because of their advanced infrastructure, specialized medical personnel, and ability to manage severe infectious conditions. According to the SNS Insider analysis, hospitals accounted for 56.86% of the market in 2025. Specialty clinics, however, are emerging as an important growth area as patients increasingly seek focused infectious disease and travel medicine services.
Rabies continues to represent a major disease segment, accounting for 31.42% of the market share in 2025. High mortality risk, vaccination initiatives, and widespread use of post-exposure prophylaxis continue to support demand for rabies-related treatment solutions. Meanwhile, leishmaniasis is expected to register the fastest growth among disease types, supported by increasing prevalence in tropical and subtropical regions and continued advances in diagnosis and therapy.
By causative agent, bacterial infections held the largest share at 41.25% in 2025. The widespread use of antibacterial therapies for diseases such as tuberculosis and leptospirosis has supported the segment’s position. Nematode infections are projected to record the fastest growth, reflecting increasing awareness, improved diagnostic capabilities, and expanding access to antiparasitic treatments in affected regions.
Antibiotics remained the leading drug class, representing 36.58% of the market in 2025. Their broad application across bacterial zoonotic infections, established treatment protocols, and availability continue to support adoption. At the same time, antifungal therapies are gaining attention as awareness of zoonotic fungal infections increases and pharmaceutical companies invest in improved treatment options.
Oral administration dominated the route-of-administration segment with a 46.68% share in 2025, supported by convenience, affordability, and patient compliance. Topical treatments are expected to grow at a faster pace as targeted therapies become more widely used for localized infections and manufacturers introduce new formulations.
Regionally, North America held the dominant position with a 39.87% share in 2025. The region benefits from advanced healthcare infrastructure, established pharmaceutical capabilities, strong research activity, and broad adoption of anti-infective treatments. The United States remains a major contributor to regional growth, supported by infectious disease surveillance, research and development, and the adoption of a One Health approach.
Asia-Pacific is expected to be the fastest-growing regional market, with a projected CAGR of 7.05% through 2035. Increasing cases of malaria, leishmaniasis, rabies, and other infections, along with improving healthcare infrastructure, vaccination initiatives, biotechnology investment, and disease surveillance programs, are creating significant opportunities. India and China are particularly important markets because of their expanding healthcare capabilities and vaccine manufacturing ecosystems.
The competitive landscape includes major pharmaceutical and healthcare companies such as Pfizer, Merck & Co., Roche, GlaxoSmithKline, Johnson & Johnson, Novartis, Sanofi, AstraZeneca, Bayer, Eli Lilly, AbbVie, Amgen, Zoetis, Boehringer Ingelheim, and other industry participants. Companies are focusing on drug development, vaccine innovation, biologics, strategic collaborations, and portfolio expansion to strengthen their positions in zoonotic disease management.
The outlook for the market remains positive as governments and healthcare organizations strengthen outbreak preparedness and adopt broader One Health strategies linking human, animal, and environmental health. Continued advances in vaccines, rapid-response therapeutics, diagnostics, and anti-infective drugs are expected to support market expansion while helping healthcare systems respond more effectively to emerging and established zoonotic threats.
About Us
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.